The Promise and Fallacy of AI/ML for Pharma R&D

Introduction/インتروダクション

October 15, 2019/2019年10月15日

Jun KURIHARA/栗原 潤
(Research Director, Canon Institute for Global Studies (CIGS)/
キヤノングローバル戦略研究所 研究主幹)
Kurihara.Jun@canon-igs.org; Kurihara.Jun@gmail.com

©2019 Jun KURIHARA
No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of the author. Disclaimer: The views expressed in this presentation are those of the author and do not necessarily reflect those of CIGS.

Today’s Seminar: Program

Opening Remarks, Introduction/開会・インتروダクション
Jun Kurihara (Research Director, CIGS)/栗原 潤 (キヤノングローバル戦略研究所 研究主幹)

I: Presentation/講演
“The Promise and Fallacy of AI/ML for Pharma R&D”
Dr. Ray Liu (Senior Director, Advanced Analytics, Takada Pharmaceutical Inc., Cambridge, MA)/
レイ・リュー (劉睿哲)氏 (武田薬品)

II: Discussion/討論
Moderator: Jun Kurihara (Research Director, CIGS)/栗原 潤 (キヤノングローバル戦略研究所 研究主幹)

Closing Remarks/閉会
Jun Kurihara (Research Director, CIGS)/栗原 潤 (キヤノングローバル戦略研究所 研究主幹)
A team from AI pharma startup Insilico Medicine, working with researchers at the University of Toronto, took 21 days to create 30,000 designs for molecules that target a protein linked with fibrosis (tissue scarring). They synthesized six of these molecules in the lab and then tested two in cells; the most promising one was tested in mice. The researchers concluded it was potent against the protein and showed “drug-like” qualities. All in all, the process took just 46 days. The research was published in Nature Biotechnology this week.

See also,

“A Breakthrough in Imaginative AI with Experimental Validation to Accelerate Drug Discovery”
—EurekAlert! September 3, 2019

"Using Advanced GANs in the discovery of drugs is a great example of cutting edge application of AI in the pharmaceutical industry - it speeds up a critical process from years to just weeks," said Christian Guttmann, Executive Director Nordic AI Institute, Professor AI at the University of New South Wales, and Senior AI Research Fellow AI at Karolinska Institute.
I: Use of AI in the Health Field: Blue-Sky Thinking?
AI systems help diagnose and prevent disease and outbreaks early on, discover treatments and drugs, propose tailored interventions and power self-monitoring tools.
(OECD, Artificial Intelligence in Society, Paris: OECD, June 2019, p. 16.)

The use of AI in this field extends beyond facilitating drug discovery to predicting the right dose for experimental drugs. Since the optimal drug dose may depend on so many variables for each individual, such as age, gender, weight, generics, proteomics, the gut microbiome, and more, it's an ideal subject for modeling and deep learning algorithms.

II: Use of AI in the Health Field: An American Experience
Advantages and Limitations of AI Methods in Health and Health Care Applications (Today's Talk)

III: Use of AI in the Health Field: A Global Solution amidst a Dire Shortage of AI-powered Human Resources
A Baltimore-based company, Insilico Medicine, Inc., applies the latest advances in artificial intelligence to drug discovery, biomarker development, and aging research.
The company’s CEO, Alexander Zhavoronkov (Александр Александрович Жаворонков), is Chief Scientific Officer of the Biogerontology Research Foundation, a UK-based registered charity supporting aging research worldwide. He is also Director of the International Aging Research Portfolio (IARP) knowledge management project, Chief Scientist of Youth Laboratories and an adjunct professor at the Moscow Institute of Physics and Technology.
He holds two Bachelor Degrees from Queen's University, a Master’s in Biotechnology from Johns Hopkins University, and a Ph.D. in Biophysics from the Moscow State University.

IV: Use of AI in the Health Field: Issues on the Horizon
(1) Intensified global competition will be fueled by nations and companies in the fields of AI development and the pharmaceutical industry.
(2) FDA has been paying close attention to the international development of both software in medical devices (SiMD) and software as a medical device (SaMD). FDA has been participating (actually chaired) an international regulators forum on SiMD and SaMD.
(3) International cooperation at a pre-competitive stage (esp. with Japan); Kyoto University-led projects (Life Intelligence Consortium (LINC), under the leadership of Prof. Yasushi Okuno, established in November 2016).